Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Palbociclib

FDA-approved product (capsule, oral), marketed as Ibrance, Palbociclib.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Palbociclib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Cancer
  • HER2 Positive Breast Carcinoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Cyclin-dependent kinase (cdk) inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against K. pneumoniae, MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA60.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli59.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae46.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Palbociclib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Palbociclib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer

    NCT07299890 · start 2025-12-20

    Registered record
    Registry ID
    NCT07299890
    Conditions
    Breast Cancer
    Interventions
    Trastuzumab and Pertuzumab Combination with Palbociclib and Exemestane
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-12-20
    Completion
    2027-11-01
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionTrastuzumab and Pertuzumab Combination with Palbociclib and Exemestane
    PhasePhase 2
    Registry statusNot yet recruiting

  • Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer

    NCT07037199 · start 2025-08-18

    Registered record
    Registry ID
    NCT07037199
    Conditions
    Advanced Breast Cancer
    Interventions
    Trastuzumab rezetecan + CDK4/6 inhibitors + endocrine therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-08-18
    Completion
    2030-06-30
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Breast Cancer
    InterventionTrastuzumab rezetecan + CDK4/6 inhibitors + endocrine therapy
    PhasePhase 2
    Registry statusRecruiting

  • Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer

    NCT07061717 · start 2025-07-01

    Registered record
    Registry ID
    NCT07061717
    Conditions
    Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
    Interventions
    Palbociclib 125mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd; Palbociclib 125mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd + Hydroxychloroquine 600mg bid; Palbociclib 200mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd + Hydroxychloroquine 600mg bid
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2025-07-01
    Completion
    2029-07-01
    Enrolment
    474

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
    InterventionPalbociclib 125mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd; Palbociclib 125mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd + Hydroxychloroquine 600mg bid; Palbociclib 200mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd + Hydroxychloroquine 600mg bid
    PhasePhase 3
    Registry statusNot yet recruiting

  • Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype

    NCT06486883 · start 2025-06-30

    Registered record
    Registry ID
    NCT06486883
    Conditions
    Advanced Breast Cancer; Advanced Breast Carcinoma; Hormone Receptor Positive Breast Carcinoma
    Interventions
    Trastuzumab deruxtecan (T-DXd, DS-8201a); CDK4/6i plus ET
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-06-30
    Completion
    2028-01
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Breast Cancer; Advanced Breast Carcinoma; Hormone Receptor Positive Breast Carcinoma
    InterventionTrastuzumab deruxtecan (T-DXd, DS-8201a); CDK4/6i plus ET
    PhasePhase 2
    Registry statusRecruiting

  • SNV4818 in Participants With Advanced Solid Tumors

    NCT06736704 · start 2025-02-20

    Registered record
    Registry ID
    NCT06736704
    Conditions
    Advanced Solid Tumors
    Interventions
    SNV4818; Fulvestrant; Palbociclib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2025-02-20
    Completion
    2027-06
    Enrolment
    320

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Solid Tumors
    InterventionSNV4818; Fulvestrant; Palbociclib
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer

    NCT06495164 · start 2024-06-24

    Registered record
    Registry ID
    NCT06495164
    Conditions
    Breast Cancer; Malignant Neoplasm of Breast
    Interventions
    Palbociclib; Aromatase inhibitor; Ribociclib; Abemaciclib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2024-06-24
    Completion
    2026-12-30
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Malignant Neoplasm of Breast
    InterventionPalbociclib; Aromatase inhibitor; Ribociclib; Abemaciclib
    PhaseNot recorded
    Registry statusActive not recruiting

  • Avelumab, Palbociclib and Axitinib in Advanced RCC

    NCT05176288 · start 2024-05-31

    Registered record
    Registry ID
    NCT05176288
    Conditions
    Advanced Clear Cell Renal Cell Carcinoma
    Interventions
    Axitinib; Palbociclib; Avelumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2024-05-31
    Completion
    2027-08-31
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Clear Cell Renal Cell Carcinoma
    InterventionAxitinib; Palbociclib; Avelumab
    PhasePhase 2
    Registry statusWithdrawn

  • Clinical Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma

    NCT06364956 · start 2024-05-15

    Registered record
    Registry ID
    NCT06364956
    Conditions
    Bladder Cancer
    Interventions
    Tislelizumab combined with two predefined dose groups of palbociclib; RP2D dose Of Tislelizumab combined with palbociclib was selected for phase II clinical trial.
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2024-05-15
    Completion
    2026-06
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBladder Cancer
    InterventionTislelizumab combined with two predefined dose groups of palbociclib; RP2D dose Of Tislelizumab combined with palbociclib was selected for phase II clinical trial.
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

    NCT06188520 · start 2023-12-05

    Registered record
    Registry ID
    NCT06188520
    Conditions
    ER+ HER2- Advanced Breast Cancer; High-grade Serous Ovarian Cancer (HGSOC)
    Interventions
    AZD8421; Camizestrant; Ribociclib; Palbociclib; Abemaciclib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2023-12-05
    Completion
    2027-08-04
    Enrolment
    564

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionER+ HER2- Advanced Breast Cancer; High-grade Serous Ovarian Cancer (HGSOC)
    InterventionAZD8421; Camizestrant; Ribociclib; Palbociclib +1 more
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • A Study to Understand the Use of Palbociclib in Canadian Patients With Breast Cancer That Has Spread to Other Organs

    NCT06003114 · start 2023-10-06

    Registered record
    Registry ID
    NCT06003114
    Conditions
    Breast Cancer
    Interventions
    Palbociclib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-10-06
    Completion
    2024-02-22
    Enrolment
    472

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionPalbociclib
    PhaseNot recorded
    Registry statusCompleted

  • Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

    NCT06062498 · start 2023-09-29

    Registered record
    Registry ID
    NCT06062498
    Conditions
    Estrogen-receptor-positive Breast Cancer; HER2/Neu-Negative Breast Cancer; Advanced Breast Cancerv; Metastatic Breast Cancer
    Interventions
    elacestrant, palbociclib, abemaciclib, ribociclib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-09-29
    Completion
    2029-07-01
    Enrolment
    174

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEstrogen-receptor-positive Breast Cancer; HER2/Neu-Negative Breast Cancer; Advanced Breast Cancerv; Metastatic Breast Cancer
    Interventionelacestrant, palbociclib, abemaciclib, ribociclib
    PhasePhase 2
    Registry statusRecruiting

  • Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer

    NCT05909397 · start 2023-08-09

    Registered record
    Registry ID
    NCT05909397
    Conditions
    Breast Cancer
    Interventions
    Vepdegestrant (ARV-471/PF-07850327); Palbociclib; Letrozole; Palbociclib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2023-08-09
    Completion
    2026-12-30
    Enrolment
    59

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionVepdegestrant (ARV-471/PF-07850327); Palbociclib; Letrozole; Palbociclib
    PhasePhase 3
    Registry statusActive not recruiting

  • Pilot Trial for Treatment of Recurrent Glioblastoma

    NCT05432518 · start 2023-06-27

    Registered record
    Registry ID
    NCT05432518
    Conditions
    Glioblastoma; Recurrent Disease; Recurrent Glioblastoma
    Interventions
    Afatinib; Dasatinib; Palbociclib; Everolimus; Olaparib
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Recruiting
    Start
    2023-06-27
    Completion
    2027-12-01
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlioblastoma; Recurrent Disease; Recurrent Glioblastoma
    InterventionAfatinib; Dasatinib; Palbociclib; Everolimus +1 more
    PhaseEarly phase 1
    Registry statusRecruiting

  • Abemaciclib, Palbociclib or Dalpiciclib Combined with Endocrine Therapy As First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer

    NCT06344780 · start 2023-05-20

    Registered record
    Registry ID
    NCT06344780
    Conditions
    Breast Cancer
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2023-05-20
    Completion
    2025-02-01
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction

    NCT05865132 · start 2023-04-06

    Registered record
    Registry ID
    NCT05865132
    Conditions
    Esophagus Squamous Cell Carcinoma
    Interventions
    Palbociclib; Afatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2023-04-06
    Completion
    2026-04
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEsophagus Squamous Cell Carcinoma
    InterventionPalbociclib; Afatinib
    PhasePhase 2
    Registry statusUnknown